BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17384651)

  • 1. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.
    Shariat SF; Zlotta AR; Ashfaq R; Sagalowsky AI; Lotan Y
    Mod Pathol; 2007 Apr; 20(4):445-59. PubMed ID: 17384651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
    Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A
    World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
    Lee K; Jung ES; Choi YJ; Lee KY; Lee A
    J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
    J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy.
    Shariat SF; Passoni N; Bagrodia A; Rachakonda V; Xylinas E; Robinson B; Kapur P; Sagalowsky AI; Lotan Y
    BJU Int; 2014 Jan; 113(1):70-6. PubMed ID: 24053584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
    Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
    J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
    Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
    Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression in patients with advanced urothelial cancer of the urinary bladder.
    Shariat SF; Bolenz C; Karakiewicz PI; Fradet Y; Ashfaq R; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Rigaud J; Müller SC; Lerner SP; Montorsi F; Sagalowsky AI; Cote RJ; Lotan Y
    BJU Int; 2010 Feb; 105(4):489-95. PubMed ID: 19659466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Cycle Markers in the Evaluation of Bladder Cancer.
    da Silva JNL; Ranzi AD; Carvalho CT; Scheide TV; Strey YTM; Graziottin TM; Bica CG
    Pathol Oncol Res; 2020 Jan; 26(1):175-181. PubMed ID: 29524168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.